Fast, Fit, and Manufacturable: Antibody Lead Decisions
28 Apr 2026
Lead Identification & Optimization
- Navigating vast sequence space: How can teams efficiently explore enormous antibody repertoires to pinpoint candidates with the right balance of affinity, specificity, and developability?
- Balancing potency with manufacturability: What methods best predict whether a high‑affinity lead will remain stable, express well, and avoid aggregation during scale‑up?
- Improving early liability detection: Which in silico or high‑throughput screening approaches most reliably flag immunogenicity, off‑target binding, or poor biophysical traits before costly downstream work?
- Accelerating optimization cycles: How can AI‑driven design, structural modeling, or directed evolution shorten the path from initial hit to optimized therapeutic lead?
- Integrating multimodal data: What frameworks help unify sequence, structural, functional, and developability data to make more confident lead‑selection decisions?
Industry Expert
